

ОБЗОРЫ REVIEWS

DOI: 10.21294/1814-4861-2018-17-4-88-98
УДК: 616.351+616.345]-036.22-084:577.22

Для цитирования: *Jafarov S., Link K.H.* Различие рака толстой и прямой кишки с точки зрения эпидемиологии, канцерогенеза, молекулярной биологии, первичной и вторичной профилактики: доклинические исследования. Сибирский онкологический журнал. 2018; 17 (4): 88–98. – doi: 10.21294/1814-4861-2018-17-4-88-98.

For citation: *Jafarov S., Link K.H.* Colon and rectal cancer are different tumor entities according to epidemiology, carcinogenesis, molecular- and tumor biology, primary and secondary prevention: preclinical evidence. Siberian Journal of Oncology. 2018; 17 (4): 88–98. – doi: 10.21294/1814-4861-2018-17-4-88-98.

РАЗЛИЧИЕ РАКА ТОЛСТОЙ И ПРЯМОЙ КИШКИ С ТОЧКИ ЗРЕНИЯ ЭПИДЕМИОЛОГИИ, КАНЦЕРОГЕНЕЗА, МОЛЕКУЛЯРНОЙ БИОЛОГИИ, ПЕРВИЧНОЙ И ВТОРИЧНОЙ ПРОФИЛАКТИКИ: ДОКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ

S. Jafarov^{1,3}, K.H. Link^{2,3}

Университетская больница Гелиос Вупперталь, Университет Виттена/Хердеке,
г. Вупперталь, Германия¹

Германия, 42283, г. Вупперталь, Heusner, 40¹

Клиника Асклепия Полайнен, г. Висбаден, Германия²

65197, г. Висбаден, Geisenheimerstr, 10. E-mail: k-h.link@asklepios.com²

Ульмский университет, г. Ульм, Германия³

Германия, 89081, г. Ульм, Helmholtzstraße, 16³

Аннотация

Введение. Рак толстой и прямой кишки – разные опухоли с клинической и биологической точек зрения. В настоящее время рак толстой и прямой кишки синонимично называют колоректальным раком. Основываясь на нашем опыте в фундаментальных и клинических исследованиях в этой области, мы пришли к выводу, что термин «колоректальный рак» необходимо пересмотреть, его нельзя использовать как обобщающее понятие. **Материал и методы.** Были проанализированы данные литературы и собственные результаты исследований, чтобы доказать или отклонить эту гипотезу. **Результаты.** Выявлены следующие очевидные различия: риск развития рака прямой кишки в 4 раза выше, чем рака толстой кишки; молекулярный канцерогенез при раке толстой кишки отличается от рака прямой кишки; физическая активность помогает предотвратить рак толстой кишки, но не прямой кишки; существуют патогистологические различия между раком прямой и толстой кишки. Кроме того, имеются значительные клинические отличия между этими злокачественными новообразованиями, такие как различная хирургическая топография и объемы операций, разные показания для назначения комбинированного лечения, поскольку рак прямой кишки менее чувствителен к химиотерапии, чем рак толстой кишки, и отличаются прогностические факторы эффективности мультимодальной терапии (например, тимидилат синтетаза и дигидропиримидин дегидрогеназа). **Дискуссия.** Рак толстой и прямой кишки определенно различаются по этиологии и формальному канцерогенезу, эффективности первичной профилактики, связанной с физической активностью, обычной и по параметрам молекулярной патологии. Согласно нашим данным, можно утверждать, что с доклинической точки зрения рак толстой и прямой кишки являются двумя разными опухолями, поскольку обладают различными репрезентативными биологическими характеристиками. Рак толстой и прямой кишки также существенно различаются по многим клиническим признакам, что было указано в отдельной статье, представленной нашей исследовательской группой. **Заключение.** Термин «колоректальный рак» не должен использоваться в фундаментальных и клинических исследованиях, как определение единого заболевания. Рак толстой кишки не одно и то же, что и рак прямой кишки. Злокачественные новообразования толстой кишки могут быть разделены на рак правой и левой половины ободочной кишки.

Ключевые слова: колоректальный рак, рак толстой кишки, рак прямой кишки, молекулярные маркеры, эпидемиология, профилактика, доклинические исследования.

COLON AND RECTAL CANCER ARE DIFFERENT TUMOR ENTITIES ACCORDING TO EPIDEMIOLOGY, CARCINOGENESIS, MOLECULAR- AND TUMOR BIOLOGY, PRIMARY AND SECONDARY PREVENTION: PRECLINICAL EVIDENCE

S. Jafarov^{1,3}, K.H. Link^{2,3}

Department of Surgery II, Helios Universitätsklinikum Wuppertal, Witten/Herdecke University, Wuppertal, Germany¹

40, Heusner Street, 42283-Wuppertal, Germany¹

Surgical Center and Asklepios Tumor Center, Asklepios Paulinen Klinik, Wiesbaden, Germany²

10, Geisenheimerstr Street, 65197-Wiesbaden, Germany²

FOGT, Ulm University, Ulm, Germany³

16, Helmholtzstraße, 89081-Ulm, Germany³

Abstract

Introduction. Colon and rectal cancer (CC, RC) are different entities from a clinical and tumor biological point of view. Up to now, both, CC and RC, are synonymously called “Colorectal Cancer” (CRC). With our experience in basic and clinical research and routine work in this field we now have come to the opinion, that the term “CRC” should definitely be questioned, and if justified, be abandoned. **Materials/Methods.** We analyzed the actual available data from the literature and our own results from the Ulm based study group FOGT to proof or reject our hypothesis. **Results.** The following evident differences were recognized: Anatomically, the risk to develop RC is 4× higher than for CC. Molecular changes in carcinogenesis in CC are different from RC. Physical activity helps to prevent CC, not RC. Pathologically there are differences between RC and CC. In addition, there are also major clinical differences between CC and RC, such as in surgical topography and– procedures, multimodal treatment (MMT) approaches (RC in MMT is less sensitive to chemotherapy than CC), and prognostic factors for the spontaneous course and for success of MMT (e.g. TS or DPD). **Discussion.** CC’s and RC’s definitely are different in parameters of causal and formal carcinogenesis, effectivity of primary prevention by physical activity, conventional and molecular pathology. According to our findings we can demand from the preclinical point of view that CC and RC are two different tumor entities in terms of various representative biological characteristics. CC and RC are also differing substantially in many clinical features, as outlined in a separate paper from our group. **Conclusion.** “CRC” should no longer be used in basic and clinical research and other fields of cancer classification as a single disease entity. CC is not the same as RC. CC might even be divided into right and left CC.

Keywords: colorectal cancer, colon cancer, rectal cancer, molecular markers, epidemiology, prevention, pre-clinical trials.

Introduction

Colon- and rectal cancer (CC and RC) up to now are regarded as a single tumor entity, “Colorectal Cancer”/CRC, in all fields of basic- and clinical research as well as in clinical practice. This is based on the assumption that CC and RC develop in the large bowel, thought to be a similar organ from the ileocecal valve up to the dentate line as boundaries to the small bowel on the oral edge and to the anal canal, sphincter ani, and skin, aborally. The term “CRC” has been based on the similar anatomical structure (Mucosa, muscular layer, serosa +/-), function (stool concentration, fluid resorption, stool transportation and excretion) of the organ, and histology of CC and RC. Our groups for decades have worked on colon- and rectal cancer in basic-, translational-, and clinical research projects. We also have been

involved in national projects to structure and improve treatment of colon- and rectal cancer patients (Interdisciplinary Ulm-based “Forschungsgruppe Oncologie Gastrointestinale Tumoren” (FOGT); German Cancer Society (DKG) -S3 Guide lines, DKG structural commission for DKG Large Bowel Centers, Surgical Group for Visceral Oncology (CAO-V)) and organized in part nationwide activities/projects for disease prevention for the Hessian and German Cancer Societies (HKG, DKG): (“1000 Mutige Männer” (a project to motivate for preventive colonoscopy), and “du bist kostbar”(nationwide DKG-projects for cancer prevention and living with cancer (www.dubistkostbar.de)). With those activities, and the associated knowledge and experience we came to the conclusion that summarizing CC and RC to “CRC” must be questioned. Therefore, we analyzed the

literature to landmark characteristics of CC and RC, such as epidemiology, carcinogenesis, prevention, clinical symptoms, diagnosis, multimodal therapy and clinical results to find out, whether there are significant homogeneities between CC and RC justifying the definition “CRC” or rejecting it. Our experience and the results of two large multimodal treatment studies, FOGT 1 (adjuvant chemotherapy of colon cancer) and FOGT 2 (adjuvant radiochemotherapy of rectal cancer) were included in the analytic set up at highest evidence levels. Rejection of the term “CRC” would divide CC and RC as self standing tumor entities. Recent publications concerning the molecular biology of these tumors support this hypothesis. In this paper we present the preclinical differences between CC and RC.

Materials and Methods

For recapitulating the basic known information we described the current anatomical/topographical definitions of the colon and the rectum, the macro- and histopathology of colon and rectal cancers in standard literature/books/actual S3 guide lines on “colorectal cancer”. Then we analyzed actual reports (papers and abstracts) in English language on the epidemiology, etiology, formal and molecular carcinogenesis, hereditary syndromes, preventive possibilities, clinical symptoms, diagnostic procedures, surgical procedures, multimodal therapies, follow up, and short term results/long term results. We analyzed more than 2000 publications available from Pubmed, Medline etc. concerning these fields between 2000-2018 using the keywords “colorectal cancer”, “colon cancer”, “rectal cancer”, “chemosensitivity of colon and rectal cancer”, “chemotherapy”, “surgery”, “radiochemotherapy”, “randomized clinical trials”, “molecular biology”, “prognostic factors”, and others. We also took informations from the German S3 Guide Lines “Colorectal Cancer” from the versions 2008 and 2013. Results from the data bases from the FOGT trials on improvement of multimodal adjuvant chemotherapy in CC (FOGT1) and adjuvant radiochemotherapy in RC (FOGT2) and associated publications [1, 2] were used to substantiate or reject our hypothesis. The results concerning the preclinical informations are presented.

Results

Anatomically/topographically the rectum is defined as large bowel up to the edge of 16 cm from the anocutaneous line. The lower third reaches up to <6 cm, the middle third from 6-12 cm, and the upper third from >12-16 cm. The upper third has an intraperitoneal position, while the two lower thirds are located extraperitoneally in the small pelvis. The upper edge of the rectum may also be defined by the confluents of the three colon tenias to a single rectal tenia. The topography of the upper third is varying between males and females. The two lower thirds

have a sophisticated topography concerning the mesorectal structures, fascias, nerval and vascular anatomy to/from and around the rectum and position adjacent to the male/female ventrally located sexual organs and pelvic vessels and – nerve structures [3–6]. The venous blood from the lower two rectal thirds is flowing via the internal iliac veins and the inferior caval vein into the lungs, from the upper third via the inferior mesenteric vein into the liver. The venous outflow of the colon is directed into the liver via the inferior (colon sigmoideum and colon descendens) and superior (transverse colon and colon ascendens) mesenteric veins into the liver. The arterial blood supply of the colon descendens, sigmoid colon and the upper rectal third comes from the inferior mesenteric artery, while the rest of the colon is supplied by the superior mesenteric artery. The lower two rectal thirds receive their arterial blood supply via the internal iliac arteries [7–10]. The lymphatic drainages of the rectum are led in parallel to the inferior mesenteric vein (upper third) or along the pararectal/internal iliac lymph streets (middle third) or along the inferior rectal artery (lower third) [11, 12]. The innervation of the rectum is supplied by the superior and inferior hypogastric plexus (superior plexus = N.sympaticus; inferior plexus = N.sympaticus and N.parsympaticus). These plexus not only are responsible for the pelvic organ function, including the lower two thirds of the rectum [12–15]. The nerve supply of the colon runs along the arterial vascular supplies as described above. Regarding the surrounding structures, the topography of the rectum, especially of the lower two thirds, is much more hazardous to the surgeon (plexus, internal iliac vessels, ureters, sexual organs etc.) than that of the colon (ureters, portal- and splenic veins, lower pancreatic edge) – of course with consequences to the skills required for the surgical procedures and the curative limits in T4 stages. Surgery of rectal cancers with the aim of sphincter preservation is significantly more demanding than surgery of colon cancer and the difficulties, such as anastomotic insufficiencies and/or nerval injuries, increase the further down the tumor is located.

The topographic position of the rectum and its function for the patient imposes more perception than the colon and for surgical treatment imposes more challenges and risks for malfunction and irreversible damage concerning continence and lesions of surrounding structures resulting in major bleeding or malfunction pelvic organs.

Macroscopically there are four forms of colon cancers: Bowel shaped and ulcerating (55-60%), polyp-cauliflower form of growth (25%), flat forms (15-20%, and diffuse infiltrating (1%). Exophytic growth is predominant in the proximal colon, while growth is endophytic ring shaped in the distal colon [16, 17]. RC may be growing exophytically, endophytically with ulcerations and intramural expansion or diffuse infiltrating with linitis plastica [12].

Colon and rectal cancers may have different macroscopic appearances.

In **formal carcinogenesis** 85-90% of the cancers arise from low grade or high grade intraepithelial neoplasias (LGIN, HGIN [18]) mainly in form of adenomas. These are classified as tubular (75%), villous (10%) or mixed (15%) with a malignant transformation risk of 4.8% (tubular), 19% (mixed), and 38.4% (villous) [14, 19]. Most of the malignant tumors are mucinous or non-mucinous adenocarcinomas, others have signet ring, anaplastic or squamous cell differentiation with worse prognosis [20]. Low risk cancers (L0) have high or intermediate differentiation (G1, G2) high risk cancers (L1) have a bad or undefinable differentiation (G3, 4) [3, 17, 18, 21].

CC's and RC's **epidemiologically** usually are registered as CRC's. The incidence of CRC in Europe is higher than in Africa or Asia, but lower than in the US [22, 23] and is associated to nutritional habits concerning fat- and meat consumption [24]. The sex distribution in CRC disease favours male (53%) vs. female (47%), but the risk to develop a RC in males is 1.5 the risk in females, while females are predominant in developing cancers in the proximal colon (46% females vs. 38% males (1.2:1)). In the last four decades there was a "shift to the right" with increasing incidences in the right hemicolon; currently 15-35% of the cancers are located in the rectum, 25% in the right hemicolon [25-30]. According to the statistics of the American Cancer Society in 2015 [31] out of 129 700 newly registered CRC's 93.090 (72%) cancers were diagnosed in the colon, and 39.610 (28%) in the rectum, resulting in a proportion of 2.5:1 (CC:RC). This may suggest that the carcinogenic risk in the colon is higher than in the rectum.

There is a shift to the right meaning that the incidence of CC is increasing, that of RC decreasing.

To our analytic calculation, however, the **carcinogenic risk** in the rectal mucosa by far exceeds that in the colon mucosa due to the fact that the area at risk in the colon definitely is larger than that of the rectum. The area simply can be related to the length of the colon (150 cm) or rectum (16cm). Thus the incidence of CC in the US in 2015 per cm of the colon is 621cm^{-1} ($93.090/150=620.6$) vs. 2479cm^{-1} ($39.610/16=2478.6$) resulting in a relation of at least 1:4. In other words, the rectal mucosa has at least 4x higher risk for malignant transformation than the colon mucosa, which either depends on various susceptibilities to carcinogens or to various carcinogenic processes in the colon and in the rectum.

Histopathologically in early CC's and RC's mucosal lesions (polypoid, nondepressed type) are more frequently located in the colon than in the rectum (right hemicolon 51%, left hemicolon 35%, rectum 14%), while submucosal lesions more frequently occur in the rectum (Figure 1a); mucosal lesions with villous components were found more frequently in the rectum

(right hemicolon 2%, left hemicolon 5%, rectum 13% [32]. The absolute values for frequency of mucosal/submucosal lesions of the depressed type are higher in the rectum than in the right colon. (Figure 1b) [32]. The Japanese authors describing this phenomenon suggest that different carcinogenic mechanisms are the reason for this differing histopathologic appearance of colon vs. rectal cancers [32].

In CC mucosal lesions are more frequent than in RC, in RC submucosal lesions are more frequent.

The difference in the incidences of **hereditary syndromes** involved in the development of CC vs. RC implicates that the **molecular carcinogenesis** in CC seems to be different from that in RC. HNPCC manifests predominantly in the colon/proximal colon, while FAP predominantly is causing the cancer in the distal colon or rectum, but also occurs in the rest of the colon [33, 34]. Various characteristic differences between HNPCC and FAP are summarized in Table 1.

Macroscopically the APC type shows polypoid growth, while the growth pattern of the MSI type is flat. MSI types more frequently occur in the right colon (44% in the right colon vs. 25% in the left colon; $p<0.01$), while polypoid cancers are more frequent in the left (59%) vs. right (40%) colon ($p<0.01$) [35]. The flat growing early precursors of early cancers are significantly more difficult to detect than the polypoid growing early cancers [35-37].

HNPCC predominantly occurs in the right colon, for APC there is no predominance. CC and RC from a molecular biological point of view may be regarded as MSI- or APC types. MSI types are more frequent in the proximal colon and flat, APC types are polypoid. CC and RC differ in their chromosomal and molecular profiles as well as in enzyme expressions. There is no clear cut boundary between rectum and descending colon [38].

When regarding all CC's vs. RC's in their molecular carcinogenic alterations, differences in molecular profiles and enzyme expressions between CC and RC become evident (Table 2). For example, MSI more frequently is detected in proximal CC's than in RC's [39-43] which is also the case in HNPCC patients [34, 44-46]. When compared to RC, proximal CC's more frequently show mutations in BRAF (Serin/Threonin-Kinase- V600E [41, 47, 48], the expression of the CPG-Island Methylator-Phänotype (CIMP) [49-51], high gene expression of HOX [50] and CDX2 [52], increased mutation of KRAS [53] and higher levels of activated MAPK-signal transduction pathways [54]. In distal CC and in RC the following changes/molecular characteristics are more frequent when compared to proximal CC: Positivity of chromosome instability / CIN) [49], stability of microsatellites (MSS) [33, 34, 55], which is also the case in FAP [56]. The genes for EGFR or HER2 are amplified [57], p53 is mutated [58, 59], Wnt-signal-pathways in carcinogenesis activated [44, 60-62] in favour of distal CC's and RC's. The importance of p53 in carcinogenesis of colon and

rectal cancer has been extensively described by Harris [63]. CC's and RC's also differ in protein expressions significantly, which are higher for Cyclin D3 and cMyc in CC ($p < 0.001$) and for Cyclin D1, Cyclin E and Nuclear beta-Catenin in RC ($p < 0.001$) [59]. High TS expression in CC correlates to better survival in the spontaneous course [58, 64, 65] or after adjuvant chemotherapy in CC [66–69]. Vice versa in RC, high TS either correlates to worse survival [70–72] or is meaningless [73]. The hereditary cancer syndromes HNPCC (2-7% of all “CRC”'s) and FAP (1% of all “CRC”'s) are differing in their molecular chromosomal changes [38]. FAP has an APC-Gene mutation (APC

type; 60% of all “CRC”'s), while in HNPCC the germ chromosomes are mutated in their DNA information for MMR-genes (MLH1, MSH2, MSH6, PMS1, and PMS2) leading to MSI (MSI type) [44, 45, 74]. CC's and RC's may be categorized according to the features of the APC type (about 2/3 of CC+RC) and the MSI type [21, 75, 76].

Innovative for the classification of “Colorectal Cancer” were the findings of an international consortium analyzing molecular, enzymatic and immunogenic features and microscopic growth patterns including angiogenesis. With their data collection, the CRC Subtyping Consortium (CRCSC) defined four




Figure 1a: Comparison of the incidences of depressed and non-depressed types of neoplastic lesions in the rectum, the left colon, and the right colon. (A) Mucosal lesions, (B) submucosal cancers. A significant difference in the macroscopic type was noted between the rectum and the colon ($p < 0.001$). The incidence of depressed submucosal cancers in the right colon was significantly higher than that in the rectum ($p = 0.0472$). [32]




Figure 1b: (A) Relationship between the location and the size of non-depressed mucosal lesions. (B) Relationship between the location and the incidence of villous components in non-depressed mucosal lesions. (C) Locations of mucosal lesions and submucosal cancers. [32]

Table 1

Differences between FAP (familial adenomatous polyposis coli) and HNPCC (hereditary non-polyposis colorectal cancer)

	FAP	HNPCC
Prevalence rate	1 % of all colon and rectal cancers	5 % "CRC"
Phenotype	> 100 polyps	Only a few polyps can be present
Genotype	APC gene mutations	Germline mutations of the DNA MMR genes
Age of onset	In most cases, from 20 to 25 years	From, on average, year 44 onwards
Localization	Colon, rectum; associated disease locations: bones, eyes, duodenum	Right colon; associated disease locations: endometrium and also (considerably rarer) stomach, ovaries, pancreas, ureter, renal pelvis, cystic ducts
Transformation to colon and/or rectum cancer	100 % to colon and/or rectum cancer	50–70 % to colon cancer

Table 2

Differences in carcinogenesis, molecular genetic profile, histopathology, and biology of sporadic colorectal cancer compared with rectal cancer

Mutation/Expression	Proximal colon cancer	Distal colon and rectum cancer	Author(s)
Chromosome instability (CIN)	NO	YES	[49, 56]
Microsatellite instability (MSI)	YES	NO	[39]
EGFR and HER2 amplification	NO	YES	[57]
CpG hypermethylation (CIMP)	YES	NO	[49]
BRAF mutation (BRAF-like)	YES	NO	[48]
KRAS	YES	NO	[59]
p53	NO	YES	[58]
HOX gene	YES	NO	[50]
CDX2 gene	YES	NO	[52]
Thymidylate synthase	YES	NO	[70, 71]
Cyclin D3 and c-Myc	YES	NO	[59]
Cyclin D1, cyclin E and nuclear β -catenin	NO	YES	[59]
Activation of MAPK-pathways	YES	NO	[54]
Activation of Wnt-pathways	NO	YES	[44]
Mucosal lesions (non-depressed type)	YES	NO	[32]
Submucosal lesions (non-depressed type)	NO	YES	[32]
Mucosal and submucosal lesions (depressed type)	YES	NO	[32]

YES – Often positive or frequent incidence, NO – often negative or rare incidence

Table 3

Effects of different prevention measures on the two cancer entities

Prevention measure	Decreased incidence	
	Colon cancer	Rectum cancer
Physical activity	YES [53, 80, 81, 84–86]	NO [81, 84–86]
Low BMI	YES [53, 86, 87]	NO [86, 87]
Reduced energy uptake	YES [53]	NO [87]
COX-2 inhibitors	NO in case of HNPCC (there are no sufficient data)	YES in case of FAP [88–90]
Aspirin	YES [91]	NO [91]

HNPCC – Hereditary non-polyposis colorectal cancer; FAP – familial adenomatous polyposis coli.

robust consensus molecular subtypes CMS1-4 [77]. Most interestingly, CMS1 tumors were frequently diagnosed in females with right sided lesions and presented with higher histopathological grade. CMS2 tumors were mainly left sided. CMS4 tumors tended to be diagnosed at more advanced stages (UICC III and IV) and displayed worse overall and relapse free survival (in the multimodal PETACCC-3 trial involving adjuvant CT in CC UICC III). After relapse (and treatment of relapse), survival was superior in CMS2 patients and very poor in the CMS1 population [77]. In our literature analysis looking at various factors relevant for CC and RC on the molecular and protein level, many of them included in the CRCSC-analysis, we found out, that the proximal colon and the distal colon+rectum show evident differences in expression (Table 2). The multi-omic analysis of CC's confirmed the substantial differences between right- and left sided CC on the molecular genetic level [78].

A difference in carcinogenic principles might also be the reason for the different effectivity of primary preventive measures by physical activity, as pointed out in a review in 2000 on the impact of nutrition and physical activity on the development of CC/RC [79]. It now has been reported by various groups that physical activity at higher levels might reduce the incidence/risk for CC [80–83] by up to 40%, but has no influence on the incidence/risk for RC [81, 84–86]. In the Cancer Prevention Study II Nutrition Cohort involving 70.403 men and 80.771 women, the risk for CC was significantly reduced by 16% (RR 0.84, 95% KI 0.59-1.20) in participants practicing actively sports (79% of all study participants), while this was not observed in RC [85]. The results of various preventive trials involving sports activities, BMI, reduced energy intake or medical intervention with COX-2-inhibitors or aspirin are summarized in Table 3.

In summary, CC differs from RC in terms of molecular biological parameters. CC may be prevented by physical activity, while this cannot be achieved to prevent RC.

Discussion

In terms of epidemiology "CRC" has varying incidences, when continents/civilizations are compared. The male: female ratio in US statistics for incidences 2006-2010 was 1.3:1 in all CRC, but 1.6:1 in RC [29]. The location during the decades shifted from the left/rectum to the right [26, 92], and meanwhile patients with cancer in the right colon are older and more frequently females than males [28]. The most frequent locations are the right hemicolon (48%) and the rectum (28%) [29]. Up to now there are no exact data to show, whether the proportion CC:RC shows a difference in the various continents analyzed. In the Western countries, two thirds of "CRC" is located in the colon, one third in the rectum [3, 23, 29, 92]. This implicates, that the colon is more susceptible to develop cancer than the rectum, which is not the case. We set the 2015 US-incidence in proportion

to the length of the organ at risk (colon 150 cm, rectum 16 cm) and came to the conclusion, that the rectum mucosa is four times more prone to malignant transformation than the colon mucosa!

In the Western countries from a macroscopic/histological point of view colon cancers may have different growth patterns than rectal cancers [22, 23, 92]. The appearance of flat lesions (depressed type) is more frequent in the colon than in the rectum [32], thus more difficult to detect as early cancers, while the polypoid nondepressed types with villous components (easier to detect) were more frequent in the rectum [32]. The authors contributed their observation to possible differences in carcinogenesis colon vs. rectum [32]. When looking at the formal carcinogenesis, one first has to begin with analyzing differences in the most frequent autosomal dominant inheritable "CRC" cancers, HNPCC and FAP. HNPCC preferably is located in the right hemicolon, with FAP cancers there is not such a clear preference, but there is a tendency to left hemicolon- or towards the rectum cancers. Both entities differ substantially in their abnormalities on the chromosomal/DNA-mutational and enzymatic levels. FAP is an obligate precancerous disease; HNPCC may still be regarded as facultative, but has an expression rate of 50-70% [21]. The basis for FAP is an inherited mutation in the APC Gene (initiation) with the consequence of several carcinogenic steps (promotion). About 60-70% of sporadic CC and RC's have the same "APC-type" formal carcinogenic pathway [21, 93–96]. In HNPCC, a mutation in the mismatch repair gene family (MMR) is the germ defect responsible for a sequence of molecular changes which eventually lead to CC or, rarely, to RC and, in addition to cancers of extracolonic adenocarcinomas (CC only: Lynch-Syndrome I, CC and extracolonic cancers: Lynch-Syndrome II) [44, 45, 74, 95, 97, 98]. The gene-defect, responsible for the HNPCC type of cancer is detected pathologically (PCR or Immunohistology) in the tumor tissue as "Microsatellite" in the inheritable syndromes, but also in sporadic cancers which are classified as MSI-type CC or RC. The in male to female proportions in tumor locations (e.g. males get more RC than females, and females more proximal CC's than males and the shift of "CRC" incidences to the right, and the preferred locations either in the (proximal) colon (HNPCC's or MSI-type noninheritable "CRC") or in the distal colon/rectum (APC type of "CRC") and our hypothesis to carcinogenic susceptibility (see above) all support our hypothesis, that CC and RC are different tumor entities in terms of carcinogenic processes. When various alterations on the chromosomal-, gene- or protein levels were analyzed in the tumor tissue, marked differences between the "proximal colon" and the "distal colon and rectum" appeared (see Table 2). The possibility to prevent CC by (high) physical activity, but not RC indirectly supports our conclusion, that major carcinogenetic processes in CC are dissimilar from RC.

Very interesting and new findings concerning the classification of CRC's were generated by the CRCSC Subtyping Consortium in 2015: The group subclassified "CRC's" from 4151 samples/patients (according to various features from the molecular up to the histopathologic and immunogenic levels (27 unique subtype labels)) into the four distinct subtypes CMS1-4. (and an additional "mixed group") using a very heterogeneous tumor population from CC and RC patients with/without surgery, with/without multimodal therapy, with a variety of multimodal treatments, and applied various analytical methods and very sophisticated biometrics. The groups CMS1-4 had various distinct biological properties. Most interestingly, two of the CMS-groups were associated to embryologically different parts of the colon: CMS1 to right sided lesions, and CMS2 mainly to the left sided lesions [77]. The tumor tissues/data were supplied by 6 different working groups who either had their data from "CRC"- or CC- samples/patients. There was no distinct differentiation between CC and RC [77]. In spite the facts that no separate views seem to have been shed on CC primary tumors as a whole vs. RC primary tumors, and that 858 patients/samples from primary tumors were excluded from the primary analysis, the new system implies, that the large bowel cancers seem to have significantly different characteristics, which eventually may become relevant for treatment individualization according to these groups. CRCSC proposes a new taxonomy of colorectal cancer reflecting significant biological differences in the gene expression-based molecular subtypes, which is supported by others [78, 99, 100]. We are thinking that this demand for a change in looking at "CRC" with a very complicated classification system is generalizing too early and mainly based on a molecular primed classification view. More facts need to be respected for dividing the term "CRC" in organ related taxonomic entities.

Various prognostic molecular or enzymatic factors have been tested in CC, RC, and "CRC" in the spontaneous courses or in multimodal therapy with the aim to have a better individualized treatment- and/or patient selection to avoid unnecessary potentially toxic CT's or RCT's. We and a few other groups [101, 102] were the first to study the potential role of TS and DPD to individualize patient selection for adjuvant/neoadjuvant and for palliative treatment in "CRC" [67, 79, 103] and conducted the first prospective randomized trial for treatment of metastases [104], always in translational projects with the USC Cancer Center in Los Angeles and the laboratory of P.V. and K. Danenberg, coworkers of the late Charles Heidelberger (teacher and inspirator of one of the authors (K.H.L.) to introduce individualization to surgical oncology). Up to now, there is a tendency in results from multimodal trials, that these molecular prognostic factors, e.g. TS and DPD, may be used for treatment individualization – with different results

in CC- vs. RC-multimodal treatment. E.g. low TS might be associated with a benefit from RCT+CT in RC, and high TS in adjuvant CT of CC. Reimers et al. have suggested a cocktail of modern prognostic factors for patient selection in neoadjuvant treatment of RC [43], however, this approach due to the lack of unanimous convincing data obtained by best methods determined in translational research consensus is far from routine yet.

Regarding our findings, we strongly suggest to accept CC and RC as different tumor entities in all aspects of experimental and clinical research. The term "CRC" should be historical.

Summary and conclusion

We collected data on various relevant levels to question the term "colorectal cancer" and, if indicated, suggest to replace it by "colon cancer" (CC) and by "rectal cancer" (RC) separately, if the tumor is located/has been the origin of the primary tumor in the corresponding location. Basic and clinical research groups should respect this change of nomenclature. With our ample experience in carcinogenesis, prevention, surgery and multimodal therapy of primary CC and RC primary tumors and their metastases and in treatment individualization by molecular/cell culture methods and on the basis of the following collected data/experiences we think, that this recommendation is justified. The CMS system suggested by the CRCSC group also suggests taking a distinct look at the broad nondifferentiating term "CRC". Our opinion, that CC and RC are distinct tumor entities is supported by the facts that CC and RC seem to be submit two different pathways in initiation and promotion (carcinogenesis: HNPPC and MSI type of CC mainly located in the proximal colon, FAP and APC type without clear preference, but a tendency to the left colon and to the rectum), have a different susceptibility to/way of carcinogenesis (rectal mucosa is four times more susceptible to malignant transformation than colon mucosa) and to preventive principles in carcinogenesis (active sports may prevent CC (up to 40%), but not RC), that tumors shift to the right and female sex is dominating in proximal (right) CC's (due to a change of carcinogenic principles). The clinical parameters of differences between CC and RC, such as in surgical techniques with morbidity/mortality and long term results, the responses and toxicities (= the benefit) of multimodal therapy (MMT) and molecular/clinical prognostic factors in the spontaneous course and after MMT, are analyzed and reported in a separate paper [105]. CC and RC have different profiles from the view of many preclinical (and clinical) parameters. In basic and translational research concerning "CRC", Colon Cancer (CC) and Rectal Cancer (RC) should be regarded as different tumor entities. CC may even be subdivided in right sided CC and left sided CC (and male vs. female).

ЛІТЕРАТУРА/REFERENCES

1. Link K.H., Kornmann M., Staib L., Redenbacher M., Kron M., Berger H.G.; Study Group Oncology of Gastrointestinal Tumors. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment. *Ann Surg.* 2005 Aug; 242(2): 178–87.
2. Kornmann M., Staib L., Wiegelt T., Kreuzer E.D., Kron M., Baumann W., Henne-Bruns D., Link K.H. Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with acid or with interferon-alpha. *Br J Cancer.* 2010 Oct 12; 103(8): 1163–72. doi: 10.1038/sj.bjc.6605871.
3. Pox C., Aretz S., Bischoff S., Graeven U., Hass M., Heußner P., Hohenberger W., Holstege A., Hübner J., Kolligs F., Kreis M., Lux P., Ockenga J., Porschen R., Post S., Rahner N., Reinacher-Schick A., Riemann J., Sauer R., Sieg A., Scheppach W., Schmitt W., Schmoll H.J., Schulmann K., Tannapfel A., Schmiegel W. S3-Leitlinie „Kolorektales Karzinom“. *Z Gastroenterol.* 2013; 51: 753–854.
4. Heald R.J., Moran B.J. Embryology and anatomy of the rectum. *Semin Surg Oncol.* 1998; 15: 66–71.
5. Köckerling F., Lippert H., Gasting I. Fortschritte in der kolorektalen Chirurgie. Hannover, Science Med, 2002. 204.
6. Winkler R., Otto P., Schiedeck T. Proktologie: Ein Leitfadens für die Praxis. 2. Aufl. Stuttgart, Thieme, 2011. 7.
7. Barleben A., Mills S. Anorectal anatomy and physiology. *Surg Clin North Am.* 2010 Feb; 90(1): 1–15. doi: 10.1016/j.suc.2009.09.001.
8. Dujovny N., Quiros R.M., Saclarides T.J. Anorectal anatomy and embryology. *Surg Oncol Clin N Am.* 2004 Apr; 13(2): 277–93.
9. Kornmann M., Staib L., Wiegelt T., Kron M., Henne-Bruns D., Link K.H., Formentini A.; Study Group Oncology of Gastrointestinal Tumors (FOGT). Differences in colon and rectal cancer chemosensitivity. *Colorectal Cancer* 2014; 3: 93–105.
10. Jafarov S., Kornmann M., Scheele J., Farah G., Hübner P., Link K.H. Differences between colon and rectal cancer. Internationaler Kongress ICRC; Ulm. 9 Oktober 2014.
11. Paulsen F., Waschke J. Sobotta, Atlas der Anatomie des Menschen. 23. Aufl. München: Elsevier, 2010. 99–100.
12. Willis S., Schumpelick V. Rektumkarzinom. in *Onkologische Chirurgie*. 3. Aufl. Berlin, Heidelberg: Springer, 2010. 713–732.
13. Schumacher G.H., Aumüller G. Topographische Anatomie des Menschen. 7. Aufl. München: Elsevier, 2004. 256–296.
14. Henne-Bruns D., Dürig M., Kremer B. Chirurgie. 3. Aufl. Stuttgart: Thieme, 2008. 201–221.
15. Schünke M., Schulte E., Schumacher U. Prometheus – Innere Organe: LernAtlas der Anatomie. 4. Aufl. Stuttgart: Thieme, 2015. 512.
16. Hiddemann W., Bartram C.R. Die Onkologie. 2. Aufl. Heidelberg: Springer-Medizin, 2010. 854.
17. Hamilton S.R., Aaltonen L.A. World Health Organisation. Classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon, IARC, 2000. 314.
18. Werner M. Allgemein Onkogenese und Tumorphathologie. in *Onkologische Chirurgie*. 3. Aufl. Berlin, Heidelberg: Springer, 2010. 4–10.
19. Hermanek P., Mansmann P.U., Altendorf-Hofmann A., Hermanek P.Jr., Riedl St., Staimmer D. Vergleichende Beurteilung der onkologischen Ergebnisqualität beim kolorektalen Carcinom. Klinikvergleiche anhand von Surrogatendpunkten? *Der Chirurg* 1999; 70: 407–414.
20. Wittekind C. Tumorklassifikationen. in Siewert JR, Rothmund M, Schumpelick V (eds): *Onkologische Chirurgie*. 3. Aufl. Berlin, Heidelberg: Springer, 2010. 20–28.
21. Tannapfel A. Präkanzerösen und molekulare Marker. in *Onkologische Chirurgie*. 3. Aufl. Berlin, Heidelberg: Springer, 2010. 14–17.
22. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. *Ann Oncol* 2007; 18: 581–592.
23. WHO Mortality Database 2009 [Internet]. URL: <https://www.health.govt.nz/system/files/documents/publications/mortality-and-demographic-data-2009.pdf> (cited 12.02.2014).
24. Riboli E. Nutrition and cancer: background and rationale of the European Prospective Investigation into Cancer and Nutrition (EPIC). *Ann Oncol.* 1992; 10: 783–791.
25. Ruf G., Hopt U., Otto F., Deschler B., Werner M., Barke A., Langer M., Schäfer O., Moser E., Brink I., Henß H. Kolorektales Karzinom, Empfehlungen zur standardisierten Diagnostik, Therapie und Nachsorge. Tumorzentrum Freiburg am Universitätsklinikum, 2005.
26. Schmidt-Decker S., Brannath J., Teichmann W. Häufigkeit und Lokalisation kolorektaler Adenome und Karzinome bei 4109 Patienten. *Dtsch med Wochenschr* 1990; 115(48): 1819–1824. doi: 10.1055/s-2008-1065231.
27. Mostafa G., Matthews B.D., Norton H.J., Kercher K.W., Sing R.F., Heniford B.T. Influence of demographics on colorectal cancer. *Ann Surg* 2004; 70: 259–264.
28. Benedix F., Meyer F., Kube R., Gasting I., Lippert H. Right- and left-sided colonic cancer – different tumour entities. *Zentralbl Chir.* 2010 Aug; 135(4): 312–7. doi: 10.1055/s-0030-1247471.
29. Siegel R., Ma J., Zou Z., Jemal A. *Cancer Statistics, 2014.* CA: Cancer J Clin 2014; 64: 9–29.
30. Link K.H., Coy P., Roitman M., Link C., Kornmann M., Staib L. Minimum volume discussion in the treatment of colon and rectal cancer: a review of the current status and relevance of surgeon and hospital volume regarding result quality and the impact on health economics. *Visc Med.* 2017 May; 33(2): 140–147. doi: 10.1159/000456044.
31. American Cancer Society: *Cancer Facts and Figures 2015.* Atlanta, Ga: American Cancer Society, 2015. [Internet] <http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf> (cited 07.01.2015).
32. Konishi K., Fujii T., Boku N., Kato S., Koba I., Ohtsu A., Tajiri H., Ochiai A., Yoshida S. Clinicopathological differences between colonic and rectal carcinomas: are they based on the same mechanism of carcinogenesis? *Gut* 1999; 45: 818–821.
33. Lynch H.T., Smyrk T.C. Classification of familial adenomatous polyposis: a diagnostic nightmare. *Am J Hum Genet* 1998; 62: 1288–1289.
34. Lynch H.T., Lynch J.F., Shaw T.G., Lubinski J. HNPCC (Lynch Syndrome): differential diagnosis, molecular genetics and management – a review. *Hered Cancer Clin Pract* 2003; 1: 7–18.
35. Nawa T., Kato J., Kawamoto H., Okada H., Yamamoto H., Kohno H., Endo H., Shiratori Y. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. *J Gastroenterol Hepatol.* 2008 Mar; 23(3): 418–23. doi: 10.1111/j.1440-1746.2007.04923.x.
36. Schmiegel W., Reinacher-Schick A., Arnold D., Graeven U., Heinemann V., Porschen R., Riemann J., Rödel C., Sauer R., Wieser M., Schmitt W., Schmoll H.-J., Seufferlein T., Kopp I., Pox C. S3-Leitlinie „Kolorektales Karzinom“. *Z Gastroenterol* 2008; 46: 799–840.
37. Lynch H.T., Smyrk T., McGinn T., Lanspa S., Cavalieri J., Lynch J., Slominski-Castor S., Cayouette M.C., Priluck I., Luce M.C. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. *Cancer* 1995; 76: 2427–2433.
38. Jafarov S., Kornmann M., Knoefel W.T., Link K.H. Unterschiede zwischen Kolonkarzinom und Rektumkarzinom. *Z Gastroenterol* 2016; 54: KV393.
39. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. *Histopathology* 2007; 50: 113–130.
40. Tian S., Roepman P., Popovici V., Michaut M., Majewski I., Salazar R., Santos C., Rosenberg R., Nitsche U., Mesker W.E., Bruin S., Tejpar S., Delorenzi M., Bernards R., Simon I. A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. *J Pathol.* 2012 Dec; 228(4): 586–95. doi: 10.1002/path.4092.
41. Budinska E., Popovici V., Tejpar S., D’Ario G., Lapique N., Sikora K.O., Di Narzo A.F., Yan P., Hodgson J.G., Weinrich S., Bosman F., Roth A., Delorenzi M. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. *J Pathol.* 2013 Sep; 231(1): 63–76. doi: 10.1002/path.4212.
42. Nehls O., Okech T., Hsieh C.J., Enzinger T., Sarbia M., Borchard F., Gruenagel H.H., Gaco V., Hass H.G., Arkenau H.T., Hartmann J.T., Porschen R., Gregor M., Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. *Br J Cancer* 2007; 96: 1409–1418.
43. Reimers M.S., Zeestraten E.C.M., Kuppen P.J.K., Liefers G.J., van de Velde C.J.H. Biomarkers in precision therapy in colorectal cancer. *Gastroenterol Rep (Oxf).* 2013 Nov; 1(3): 166–83. doi: 10.1093/gastro/got022.
44. Peltomaki P., Vasen H.F. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. *Gastroenterology.* 1997 Oct; 113(4): 1146–58.
45. Vogelsang H., Holinski-Feder E., Gross M., Keller G., Keller M., Kopp R., Lohse P., Müller-Koch Y., Neutzling A. Hereditäre Tumorerkrankungen des Gastrointestinaltrakts. in *Manual Gastrointestinale Tumoren*. 6. Aufl. München, Zuckschwerdt, 2001. 261–283.
46. Kullmann F., Bocker T., Schölmerich J., Rüschoff J. Microsatellite instability – a new aspect in genetics and molecular biology of hereditary nonpolyposis and sporadic colorectal tumors. *Z Gastroenterol* 1996; 34(12): 813–822.
47. Rad R., Cadinanos J., Rad L., Varela I., Strong A., Kriegl L., Constantino-Casas F., Eser S., Hieber M., Seidler B., Price S., Fraga M.F., Calvanese V., Hoffman G., Pongstingl H., Schneider G., Yusa K., Grove C., Schmid R.M., Wang W., Vassiliou G., Kirchner T., McDermott U., Liu P., Saur D., Bradley A. A genetic progression model of Braf (V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. *Cancer Cell* 2013; 24: 15–29. doi: 10.1016/j.ccr.2013.05.014.
48. Popovici V., Budinska E., Tejpar S., Weinrich S., Estrella H., Hodgson G., Van Cutsem E., Xie T., Bosman F.T., Roth A.D., Delorenzi M.

- Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. *J Clin Oncol*. 2012 Apr 20; 30(12): 1288–95. doi: 10.1200/JCO.2011.39.5814.
49. Oginio S., Goel A. Molecular classification and correlates in colorectal cancer. *J Mol Diagn*. 2008 Jan; 10(1): 13–27. doi: 10.2353/jmol.2008.070082.
50. Sanz-Pamplona R., Cordero D., Berenguer A., Lejbkiewicz F., Rennert H., Salazar R., Biondo S., Sanjuan X., Pujana M.A., Rozek L., Giordano T.J., Ben-Izhak O., Cohen H.I., Trougouboff P., Bejhar J., Sova Y., Rennert G., Gruber S.B., Moreno V. Gene expression differences between colon and rectal tumors. *Clin Cancer Res*. 2011 Dec 1; 17(23): 7303–12. doi: 10.1158/1078-0432.CCR-11-1570.
51. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. *N Engl J Med*. 2009 Dec 17; 361(25): 2449–60. doi: 10.1056/NEJMra0804588.
52. Rozek L.S., Lipkin S.M., Fearon E.R., Hanash S., Giordano T.J., Greenson J.K., Kuick R., Misek D.E., Taylor J.M., Douglas J.A., Rennert G., Gruber S.B. CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. *Cancer Res* 2005; 65: 5488–5492. doi: 10.1158/0008-5472.CAN-04-3645.
53. Slattery M.L., Potter J.D., Caan B., Edwards S., Coates A., Ma K.N., Berry T.D. Energy balance and colon cancer – beyond physical activity. *Cancer Res* 1997; 57: 75–80.
54. Iacopetta B. Are there two sides to colorectal cancer? *Int J Cancer*. 2002 Oct 10; 101(5): 403–8. doi: 10.1002/ijc.10635.
55. Watanabe T., Kobunji T., Toda E., Yamamoto Y., Kanazawa T., Kazama Y., Tanaka J., Tanaka T., Konishi T., Okayama Y., Sugimoto Y., Oka T., Sasaki S., Muto T., Nagawa H. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. *Cancer Res*. 2006 Oct 15; 66(20): 9804–8.
56. Smith K.J., Johnson K.A., Bryan T.M., Hill D.E., Markowitz S., Willson J.K., Paraskeva C., Petersen G.M., Hamilton S.R., Vogelstein B. The APC gene product in normal and tumor cells. *Proc Natl Acad Sci U S A*. 1993 Apr 1; 90(7): 2846–50.
57. Missiaglia E., Jacobs B., D'Ario G., Di Narzo A.F., Sonesson C., Budinska E., Popovici V., Vecchione L., Gerster S., Yan P., Roth A.D., Klingbiel D., Bosman F.T., Delorenzi M., Tejpar S. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. *Ann Oncol*. 2014 Oct; 25(10): 1995–2001. doi: 10.1093/annonc/mdl275.
58. Klump B., Nehls O., Okech T., Hsieh C.J., Gaco V., Gittinger F.S., Sarbia M., Borchard F., Greschniok A., Gruenagel H.H., Porschen R., Gregor M. Molecular lesions in colorectal cancer: impact on prognosis? *Int J Colorectal Dis*. 2004 Jan; 19(1): 23–42. doi: 10.1007/s00384-003-0499-7.
59. Slattery M.L., Curtin K., Wolff R.K., Boucher K.M., Sweeney C., Edwards S., Caan B.J., Samowitz W. A comparison of colon and rectal somatic DNA alterations. *Dis Colon Rectum*. 2009 Jul; 52(7): 1304–11. doi: 10.1007/DCR.0b013e3181a0e5df.
60. Aamodt R., Jonsdottir K., Andersen S.N., Bondi J., Bukholm G., Bukholm I.R.K. Differences in protein expression and gene amplification of cyclins between colon and rectal adenocarcinomas. *Gastroenterol Res Pract*. 2009; 2009: 285830. doi: 10.1155/2009/285830.
61. Chung D.C. The genetic basis of colorectal cancer: Insights into critical pathways of tumorigenesis. *Gastroenterology*. 2000 Sep; 119(3): 854–65.
62. Mann B., Gelos M., Siedow A., Hanski M.L., Gratchev A., Ilyas M., Bodmer W.F., Moyer M.P., Riecken E.O., Buhr H.J., Hanski C. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signalling in human colorectal carcinomas. *Proc Natl Acad Sci USA*. 1999 Feb 16; 96(4): 1603–8.
63. Harris C.C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. *N Engl J Med* 1993; 329: 1318–1327. doi: 10.1056/NEJM199310283291807.
64. Spears C.P., Gustavsson B.G., Berne M., Frösing R., Bernstein L., Hayes A.A. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. *Cancer Res*. 1988 Oct 15; 48(20): 5894–900.
65. Lenz H.J., Danenberg K.D., Leichman C.G., Florentine B., Johnston P.G., Groshen S., Zhou L., Xiong Y.P., Danenberg P.V., Leichman L.P. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. *Clin Cancer Res* 1998; 4: 1227–1234.
66. Takenou T., Nagawa H., Matsuda K., Fuji S., Nita M.E., Hatano K., Kitayama J., Tsuruo Y., Muto T. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. *Ann Surg Oncol* 2000; 7: 193–198.
67. Kornmann M., Schwabe W., Sander S., Kron M., Sträter J., Polat S., Kettner E., Weiser H.F., Baumann W., Schramm H., Häusler P., Ott K., Behnke D., Staib L., Beger H.G., Link K.H. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels. Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. *Clin Cancer Res* 2003; 9: 4116–4124.
68. Donada M., Bonin S., Nardon E., De Pellegrin A., Decorti G., Stanta G. Thymidylate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-fluorouracil independently of microsatellite instability. *J Cancer Res Clin Oncol*. 2011 Feb; 137(2): 201–10. doi: 10.1007/s00432-010-0872-1.
69. Edler D., Kressner U., Ragnhammar P., Johnston P.G., Magnusson I., Glimelius B., Pahlman L., Lindmark G., Blomgren H. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. *Clin Cancer Res* 2000; 6: 488–492.
70. Edler D., Hallström M., Johnston P.G., Magnusson I., Ragnhammar P., Blomgren H. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. *Clin Cancer Res* 2000; 6: 1378–1384.
71. Liersch T., Langer C., Ghadimi B.M., Kulle B., Aust D.E., Baretton G.B., Schwabe W., Häusler P., Becker H., Jakob C. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. *J Clin Oncol* 2006; 24: 4062–4068.
72. Jakob C., Liersch T., Meyer W., Baretton G.B., Schwabe W., Häusler P., Kulle B., Becker H., Aust D.E. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. *Am J Surg Pathol* 2006; 30: 1169–1174. doi: 10.1097/01.pas.0000213302.13435.6e.
73. Conradi L.C., Bleckmann A., Schirmer M., Sprenger T., Jo P., Homayounfar K., Wolff H.A., Rothe H., Middel P., Becker H., Ghadimi M.B., Beissbarth T., Liersch T. Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. *Ann Surg Oncol*. 2011 Sep; 18(9): 2442–52. doi: 10.1245/s10434-011-1608-4.
74. Rijcken F.E., Hollema H., Kleibeuker J.H. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. *Gut* 2002; 50: 382–386.
75. Petersen G.M. Knowledge of the adenomatous polyposis coli gene and its clinical application. *Ann Med* 1994; 26: 205–208.
76. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. *Cell* 1996; 87: 159–170.
77. Guinney J., Dienstmann R., Wang X., de Reyniès A., Schlicker A., Sonesson C., Marisa L., Roepman P., Nyamundanda G., Angelino P., Bot B.M., Morris J.S., Simon I.M., Gerster S., Fessler E., De Sousa E., Melo F., Missiaglia E., Ramay H., Barras D., Homiczko K., Maru D., Manayam G.C., Broom B., Boige V., Perez-Villamil B., Laderas T., Salazar R., Gray J.W., Hanahan D., Taberero J., Bernards R., Friend S.H., Laurent-Puig P., Medema J.P., Sadanandam A., Wessels L., Delorenzi M., Kopetz S., Vermeulen L., Tejpar S. The consensus molecular subtypes of colorectal cancer. *Nat Med*. 2015 Nov; 21(11): 1350–6. doi: 10.1038/nm.3967.
78. Hu W., Yang Y., Li X., Huang M., Xu F., Ge W., Zhang S., Zheng S. Multi-omics approach reveals distinct differences in left- and right-sided colon cancer. *Mol Cancer Res*. 2018 Mar; 16(3): 476–485. doi: 10.1158/1541-7786.MCR-17-0483.
79. Link K.H., Heeckt P., Klein D., Schatz M. Ernährung & Krebs, Einfluss der Diät bei der Entstehung und Behandlung von Tumorerkrankungen. Ulm: Fabri-Verlag, 2000. 128.
80. Macfarlane G.J., Lowenfels A.B. Physical activity and colon cancer. *Eur J Cancer Prev*. 1994; 3: 393–398.
81. Halle M., Schoenberg M.H. Körperliche Aktivität in der Prävention und Therapie des kolorektalen Karzinoms. *Dtsch Arztebl Int* 2009; 106: 722–727.
82. McTiernan A. Physical activity after cancer: physiologic outcomes. *Cancer Invest* 2004; 22: 68–81.
83. Giovannucci E., Ascherio A., Rimm E.B., Colditz G.A., Stampfer M.J., Willett W.C. Physical activity, obesity and risk for colon cancer and adenoma in men. *Ann Intern Med*. 1995 Mar 1; 122(5): 327–34.
84. Gerhardsson de Verdier M., Steineck G., Hagman U., Rieger A., Norell S.E. Physical activity and colon cancer: a case-referent study in Stockholm. *Int J Cancer*. 1990; 46: 985–989.
85. Chao A., Connell C.J., Jacobs E.J., McCullough M.L., Patel A.V., Calle E.E., Cokkinides V.E., Thun M.J. Amount, type, and timing of recreational physical activity in relation to colon and rectal cancer in older adults: the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev*. 2004 Dec; 13(12): 2187–95.
86. Larsson S.C., Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. *Am J Clin Nutr* 2007; 86: 556–565.
87. Friedenreich C., Norat T., Steindorf K., Boutron-Ruault M.C., Pischon T., Mazuir M., Clavel-Chapelon F., Linseisen J., Boeing H., Bergman M., Johnsen N.F., Tjønneland A., Overvad K., Mendez M., Quiros J.R., Martinez C., Dorransoro M., Navarro C., Gurrea A.B., Bingham S., Khaw K.T., Allen N., Key T., Trichopoulou A., Trichopoulos D., Orfanou N.,

Krogh V, Palli D, Tumino R, Panico S, Vineis P, Bueno-de-Mesquita H.B., Peeters P.H., Monninkhof E., Berglund G., Manjer J., Ferrari P., Sliani N., Kaaks R., Riboli E. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev.* 2006 Dec; 15(12): 2398–407.

88. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B., Godio L., Patterson S., Rodriguez-Bigas M.A., Jester S.L., King K.L., Schumacher M., Abbruzzese J., DuBois R.N., Hittelman W.N., Zimmerman S., Sherman J.W., Kelloff G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med.* 2000 Jun 29; 342(26): 1946–52.

89. Higuchi T., Iwama T., Yoshinaga K., Toyooka M., Taketo M.M., Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. *Clin Cancer Res.* 2003 Oct 15; 9(13): 4756–60.

90. Almendingen K., Larsen L.N., Fausa O., Bratlie J., Hostmark A.T., Aabakken L. Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP. *Fam Cancer.* 2010 Dec; 9(4): 571–80. doi: 10.1007/s10689-010-9365-2.

91. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., Meade T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet.* 2010 Nov 20; 376(9754): 1741–50. doi: 10.1016/S0140-6736(10)61543-7.

92. Ritz J.P., Buhr H.J. Kolonkarzinom. in *Onkologische Chirurgie*. 3. Aufl. Berlin, Heidelberg: Springer, 2010. 694–711.

93. Weitz J., Koch M., Debus J., Höhler T., Galle P.R., Büchler M.W. Colorectal cancer. *Lancet* 2005; 365: 153–165. doi: 10.1016/S0140-6736(05)17706-X.

94. Senninger N., Colombo-Benkmann M. *Chirurgie von Kolon- und Rektum: Aktuelle Trends und Therapie*. Münster: Philippka, 2002. 9.

95. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal-tumor development. *N Engl J Med.* 1988 Sep 1; 319(9): 525–32.

96. Toribara N.W., Sleisenger M.H. Screening for colorectal cancer. *N Engl J Med.* 1995; 332: 861–867. doi: 10.1056/NEJM199503303321306.

97. Vasen H.F., Moslein G., Alonso A., Bernstein L., Bertario L., Blan-co I., Burn J., Capella G., Engel C., Frayling I., Friedl W., Hes F.J., Hodgson S., Mecklin J.P., Moller P., Nagengast F., Parc Y., Renkonen-Sinisalo L., Sampson J.R., Stormorken A., Wijnen J. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). *J Med Genet.* 2007; 44: 353–362. doi: 10.1136/jmg.2007.048991.

98. Vasen H.F., Watson P., Mecklin J.P., Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999; 116: 1453–1456.

99. Holch J.W., Ricard I., Stintzing S., Modest D.P., Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *Eur J Cancer* 2017; 70: 87–98.

100. Siegmund-Schultze N. Kolorektale Karzinome: Die Lage des Primarius zählt. *Dtsch Arztebl* 2017; 114: 20.

101. Johnston P.G., Fischer E.R., Rockette H.E., Fisher B., Wolmark N., Drake J.C., Chabner B.A., Allegra C.J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. *J Clin Oncol.* 1994 Dec; 12(12): 2640–7.

102. Edler D., Glimelius B., Hallström M., Jakobsen A., Johnston P.G., Magnusson I., Ragnhammar P., Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. *J Clin Oncol* 2002; 20: 1721–1728. doi: 10.1200/JCO.2002.07.039.

103. Kornmann M., Link K.H., Lenz H.J., Pillasch J., Metzger R., Butzer U., Leder G.H., Weindel M., Safi F., Danenberg K.D., Beger H.G., Danenberg P.V. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. *Cancer Lett* 1997; 118: 29–35.

104. Kornmann M., Hebart H., Danenberg K., Goeb R., Staib L., Kron M., Henne-Bruns D., Danenberg P., Link K.H. Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial. *Eur J Cancer* 2012; 48: 1443–1451. doi: 10.1016/j.ejca.2011.11.007.

105. Link K.H., Coy P., Roitman M., Link C., Kornmann M., Staib L. Minimum Volume Discussion in the Treatment of Colon and Rectal Cancer: A Review of the Current Status and Relevance of Surgeon and Hospital Volume regarding Result Quality and the Impact on Health Economics. *Visc Med.* 2017 May; 33(2): 140–147. doi: 10.1159/000456044.

Received 12.07.18

Accepted 09.08.18

Funding

This study required no funding.

Conflict of interest

The authors declare that they have no conflict of interest.

ABOUT THE AUTHORS

S. Jafarov, Department of Surgery II, Helios Universitätsklinikum Wuppertal, Witten/Herdecke University (Wuppertal, Germany); Ulm University (Ulm, Germany).

Karl Heinrich Link, Professor, Surgical Center and Asklepios Tumor Center, Asklepios Paulinen Klinik (Wiesbaden, Germany); Ulm University (Ulm, Germany).

СВЕДЕНИЯ ОБ АВТОРАХ

S. Jafarov, Университетская больница Гелиос Вупперталь, Университет Виттена/Хердеке (г. Вупперталь, Германия); Ульмский университет (г. Ульм, Германия).

Karl Heinrich Link, профессор, Клиника Асклепия Полайнен (г. Висбаден, Германия); Ульмский университет (г. Ульм, Германия). Authors ID (Scopus): 15035694200.

Финансирование

Авторы данной статьи подтвердили отсутствие финансовой поддержки.

Конфликт интересов

Авторы объявляют, что у них нет конфликта интересов.

Поступила 12.07.18

Принята в печать 09.08.18